SV40 TAg mouse models of cancer

Seminars in Cell and Developmental Biology

Volumn 27, Issue , 2014, Pages 61-73

  Colvin, Emily K ^a   Weir, Chris ^a   Ikin, Rowan J ^a   Hudson, Amanda L ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer; Mouse model; SV40; Transgenic

Indexed keywords

BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER RESEARCH; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MESOTHELIOMA; MOUSE MODEL; NONHUMAN; PANCREAS CANCER; PERSONALIZED MEDICINE; PROSTATE CANCER; REVIEW; SIMIAN VIRUS 40; TRANSGENIC ORGANISM; ANIMAL; EXPERIMENTAL NEOPLASM; GENETICS; TRANSGENIC MOUSE; VIROLOGY;

ANIMALIA;

VIRUS T ANTIGEN;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; HUMANS; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; SIMIAN VIRUS 40;

EID: 84901285885     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.02.004     Document Type: Review

References (175)

1. Jaenisch R., Mintz B. Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. Proc Natl Acad Sci USA 1974, 71(4):1250-1254.
2. Brinster R.L., Chen H.Y., Messing A., van Dyke T., Levine A.J., Palmiter R.D. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 1984, 37(2):367-379.
3. Gross L. A filterable agent: recovered from Ak leukemic extracts, causing salivary gland carcinomas in C3H mice. Proc Soc Exp Biol Med 1953, 83(2):414-421.
4. Sweet B.H., Hilleman M.R. The vacuolating virus, S.V. 40. Proc Soc Exp Biol Med 1960, 105:420-427.
5. Stewart S.E., Eddy B.E., Borgese N. Neoplasms in mice inoculated with a tumor agent carried in tissue culture. J Natl Cancer Inst 1958, 20(6):1223-1243.
6. Vogt M., Dulbecco R. Virus-cell interaction with a tumor-producing virus. Proc Natl Acad Sci USA 1960, 46(3):365-370.
7. Butel J.S. Patterns of polyomavirus SV40 infections and associated cancers in humans: a model. Curr Opin Virol 2012, 2(4):508-514.
8. Vilchez R.A., Kozinetz C.A., Butel J.S. Conventional epidemiology and the link between SV40 and human cancers. Lancet Oncol 2003, 4(3):188-191.
9. Ito Y., Brocklehurst J.R., Dulbecco R. Virus-specific proteins in the plasma membrane of cells lytically infected or transformed by pol-oma virus. Proc Natl Acad Sci USA 1977, 74(10):4666-4670.
10. Ito Y., Spurr N., Dulbecco R. Characterization of polyoma virus T antigen. Proc Natl Acad Sci USA 1977, 74(3):1259-1263.
11. Lane D.P., Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979, 278(5701):261-263.
12. Linzer D.I., Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979, 17(1):43-52.
13. Fiers W., Contreras R., Haegemann G., Rogiers R., Van de Voorde A., Van Heuverswyn H. Complete nucleotide sequence of SV40 DNA. Nature 1978, 273(5658):113-120.
14. Chen S., Paucha E. Identification of a region of simian virus 40 large T antigen required for cell transformation. J Virol 1990, 64(7):3350-3357.
15. Ihler F., Vetter E.V., Pan J., Kammerer R., Debey-Pascher S., Schultze J.L. Expression of a neuroendocrine gene signature in gastric tumor cells from CEA 424-SV40 large T antigen-transgenic mice depends on SV40 large T antigen. PLoS ONE 2012, 7(1):e29846.
16. Atkin S.J., Griffin B.E., Dilworth S.M. Polyoma virus and simian virus 40 as cancer models: history and perspectives. Semin Cancer Biol 2009, 19(4):211-217.
17. Cheng J., DeCaprio J.A., Fluck M.M., Schaffhausen B.S. Cellular transformation by Simian Virus 40 and murine polyoma virus T antigens. Semin Cancer Biol 2009, 19(4):218-228.
18. Martini F., Iaccheri L., Lazzarin L., Carinci P., Corallini A., Gerosa M. SV40 early region and large T antigen in human brain tumors: peripheral blood cells, and sperm fluids from healthy individuals. Cancer Res 1996, 56(20):4820-4825.
19. Martini F., Lazzarin L., Iaccheri L., Vignocchi B., Finocchiaro G., Magnani I. Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. Cancer 2002, 94(4):1037-1048.
20. Vilchez R.A., Butel J.S. SV40 in human brain cancers and non-Hodgkin's lymphoma. Oncogene 2003, 22(33):5164-5172.
21. Testa J.R., Carbone M., Hirvonen A., Khalili K., Krynska B., Linnainmaa K. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res 1998, 58(20):4505-4509.
22. Gazdar A.F., Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 2003, 5(3):177-181.
23. Qi F., Carbone M., Yang H., Gaudino G. Simian virus 40 transformation: malignant mesothelioma and brain tumors. Expert Rev Respir Med 2011, 5(5):683-697.
24. Lopez-Rios F., Illei P.B., Rusch V., Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 2004, 364(9440):1157-1166.
25. Manfredi J.J., Dong J., Liu W.J., Resnick-Silverman L., Qiao R., Chahinian P. Evidence against a role for SV40 in human mesothelioma. Cancer Res 2005, 65(7):2602-2609.
26. Shah K.V. SV40 and human cancer: a review of recent data. Int J Cancer 2007, 120(2):215-223.
27. Shivapurkar N., Takahashi T., Reddy J., Zheng Y., Stastny V., Collins R. Presence of simian virus 40 DNA sequences in human lymphoid and hematopoietic malignancies and their relationship to aberrant promoter methylation of multiple genes. Cancer Res 2004, 64(11):3757-3760.
28. Carbone M., Rizzo P., Procopio A., Giuliano M., Pass H.I., Gebhardt M.C. SV40-like sequences in human bone tumors. Oncogene 1996, 13(3):527-535.
29. Heinsohn S., Szendroi M., Bielack S., Stadt U.Z., Kabisch H. Evaluation of SV40 in osteosarcoma and healthy population: a Hungarian-German study. Oncol Rep 2009, 21(2):289-297.
30. Garcea R.L., Imperiale M.J. Simian virus 40 infection of humans. J Virol 2003, 77(9):5039-5045.
31. Poulin D.L., DeCaprio J.A. Is there a role for SV40 in human cancer?. J Clin Oncol 2006, 24(26):4356-4365.
32. Delbue S., Comar M., Ferrante P. Review on the relationship between human polyomaviruses-associated tumors and host immune system. Clin Dev Immunol 2012, 2012:542092.
33. Palmiter R.D., Chen H.Y., Messing A., Brinster R.L. SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumours in transgenic mice. Nature 1985, 316(6027):457-460.
34. Van Dyke T.A., Finlay C., Miller D., Marks J., Lozano G., Levine A.J. Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. J Virol 1987, 61(6):2029-2032.
35. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315(6015):115-122.
36. Teitelman G., Alpert S., Hanahan D. Proliferation: senescence, and neoplastic progression of beta cells in hyperplasic pancreatic islets. Cell 1988, 52(1):97-105.
37. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339(6219):58-61.
38. Christofori G., Naik P., Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994, 369(6479):414-418.
39. Naik P., Karrim J., Hanahan D. The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev 1996, 10(17):2105-2116.
40. Dietrich W.F., Radany E.H., Smith J.S., Bishop J.M., Hanahan D., Lander E.S. Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16. Proc Natl Acad Sci USA 1994, 91(20):9451-9455.
41. Parangi S., et al. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res 1995, 55(24):6071-6076.
42. Shi Y.P., Naik P., Dietrich W.F., Gray J.W., Hanahan D., Pinkel D. DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice. Genes Chromosomes Cancer 1997, 19(2):104-111.
43. Hodgson G., Hager J.H., Volik S., Hariono S., Wernick M., Moore D., et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet 2001, 29(4):459-464.
44. Olson P., Lu J., Zhang H., Shai A., Chun M.G., Wang Y., et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009, 23(18):2152-2165.
45. Gannon G., Mandriota S.J., Cui L., Baetens D., Pepper M.S., Christofori G. Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res 2002, 62(2):603-608.
46. Inoue M., Hager J.H., Ferrara N., Gerber H.P., Hanahan D. VEGF-A has a critical: nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002, 1(2):193-202.
47. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2(10):737-744.
48. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006, 103(33):12493-12498.
49. Shchors K., Nozawa H., Xu J., Rostker F., Swigart-Brown L., Evan G., et al. Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis. Oncogene 2013, 32(4):502-513.
50. Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001, 20(4):672-682.
51. Wang D.G., Johnston C.F., Anderson N., Sloan J.M., Buchanan K.D. Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. J Pathol 1995, 175(4):397-401.
52. Bartz C., Ziske C., Wiedenmann B. p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells. Gut 1996, 38(3):403-409.
53. Jiao Y., Shi C., Edil B.H., de Wilde R.F., Klimstra D.S., Maitra A., et al. DAXX/ATRX: MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331(6021):1199-1203.
54. Hu W., Feng Z., Modica I., Klimstra D.S., Song L., Allen P.J., et al. Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 2010, 1(4):360-368.
55. Chung D.C., Smith A.P., Louis D.N., Graeme-Cook F., Warshaw A.L., Arnold A. Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clin Endocrinol (Oxf) 1997, 47(5):523-528.
56. Tang L.H., Contractor T., Clausen R., Klimstra D.S., Du Y.C., Allen P.J., et al. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res: Off J Am Assoc Cancer Res 2012, 18(17):4612-4620.
57. Yachida S., Vakiani E., White C.M., Zhong Y., Saunders T., Morgan R., et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012, 36(2):173-184.
58. Hunter K.E., Quick M.L., Sadanandam A., Hanahan D., Joyce J.A. Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE 2013, 8(5):e64472.
59. Chiu C.W., Nozawa H., Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol: Off J Am Soc Clin Oncol 2010, 28(29):4425-4433.
60. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231.
61. Yao J.C., Shah M.H., Ito T., Bohas C.L., Wolin E.M., Van Cutsem E., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):514-523.
62. Asa S.L., Lee Y.C., Drucker D.J. Development of colonic and pancreatic endocrine tumours in mice expressing a glucagon-SV40T antigen transgene. Virchows Arch: Int J Pathol 1996, 427(6):595-606.
63. Efrat S., Teitelman G., Anwar M., Ruggiero D., Hanahan D. Glucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic alpha cells. Neuron 1988, 1(7):605-613.
64. Lee Y.C., Asa S.L., Drucker D.J. Glucagon gene 5'-flanking sequences direct expression of simian virus 40 large T antigen to the intestine: producing carcinoma of the large bowel in transgenic mice. J Biol Chem 1992, 267(15):10705-10708.
65. Rindi G., Efrat S., Ghatei M.A., Bloom S.R., Solcia E., Polak J.M. Glucagonomas of transgenic mice express a wide range of general neuroendocrine markers and bioactive peptides. Virchows Arch A Pathol Anat Histopathol 1991, 419(2):115-129.
66. Behringer R.R., Peschon J.J., Messing A., Gartside C.L., Hauschka S.D., Palmiter R.D., et al. Heart and bone tumors in transgenic mice. Proc Natl Acad Sci USA 1988, 85(8):2648-2652.
67. Knowles B.B., McCarrick J., Fox N., Solter D., Damjanov I. Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid gene. Am J Pathol 1990, 137(2):259-262.
68. Wilkie T.M., Schmidt R.A., Baetscher M., Messing A. Smooth muscle and bone neoplasms in transgenic mice expressing SV40T antigen. Oncogene 1994, 9(10):2889-2895.
69. Jensen N.A., Rodriguez M.L., Garvey J.S., Miller C.A., Hood L. Transgenic mouse model for neurocristopathy: Schwannomas and facial bone tumors. Proc Natl Acad Sci USA 1993, 90(8):3192-3196.
70. Jensen N.A., Smith G.M., Shine H.D., Garvey J.S., Hood L. Distinct hypomyelinated phenotypes in MBP-SV40 large T transgenic mice. J Neurosci Res 1993, 34(3):257-264.
71. Molyneux S.D., Di Grappa M.A., Beristain A.G., McKee T.D., Wai D.H., Paderova J., et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest 2010, 120(9):3310-3325.
72. Ng A.J., Mutsaers A.J., Baker E.K., Walkley C.R. Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res 2012, 2(1):19.
73. Suda Y., Aizawa S., Hirai S., Inoue T., Furuta Y., Suzuki M., et al. Driven by the same Ig enhancer and SV40T promoter ras induced lung adenomatous tumors: myc induced pre-B cell lymphomas and SV40 large T gene a variety of tumors in transgenic mice. EMBO J 1987, 6(13):4055-4065.
74. Inoue T., Hirabayashi Y., Mitsui H., Furuta Y., Suda Y., Aizawa S., et al. Experimental model for MDS-like myelodysplasia in transgenic mice harboring the SV40 large-T antigen under an immunoglobulin enhancer. Leukemia 1994, 8(Suppl. 1):S202-S205.
75. ter Brugge P.J., Ta V.B., de Bruijn M.J., Keijzers G., Maas A., van Gent D.C., et al. A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen. Blood 2009, 114(1):119-127.
76. Kil L.P., de Bruijn M.J., van Hulst J.A., Langerak A.W., Yuvaraj S., Hendriks R.W. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res 2013, 3(1):71-83.
77. Zenz T., Mertens D., Kuppers R., Dohner H., Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010, 10(1):37-50.
78. Ouillette P., Collins R., Shakhan S., Li J., Li C., Shedden K., et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res 2011, 17(21):6778-6790.
79. Maroulakou I.G., Anver M., Garrett L., Green J.E. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994, 91(23):11236-11240.
80. Shibata M.A., Jorcyk C.L., Liu M.L., Yoshidome K., Gold L.G., Green J.E. The C3(1)/SV40T antigen transgenic mouse model of prostate and mammary cancer. Toxicol Pathol 1998, 26(1):177-182.
81. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995, 92(8):3439-3443.
82. Gingrich J.R., Barrios R.J., Kattan M.W., Nahm H.S., Finegold M.J., Greenberg N.M. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997, 57(21):4687-4691.
83. Gingrich J.R., Barrios R.J., Morton R.A., Boyce B.F., DeMayo F.J., Finegold M.J., et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996, 56(18):4096-4102.
84. Irshad S., Abate-Shen C. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev 2013, 32(1-2):109-122.
85. Parisotto M., Metzger D. Genetically engineered mouse models of prostate cancer. Mol Oncol 2013, 7(2):190-205.
86. Williams T.M., Hassan G.S., Li J., Cohen A.W., Medina F., Frank P.G., et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 2005, 280(26):25134-25145.
87. Abdulkadir S.A., Qu Z., Garabedian E., Song S.K., Peters T.J., Svaren J., et al. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 2001, 7(1):101-107.
88. Kaplan-Lefko P.J., Sutherland B.W., Evangelou A.I., Hadsell D.L., Barrios R.J., Foster B.A., et al. Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. Oncogene 2008, 27(20):2868-2876.
89. Majeed N., Blouin M.J., Kaplan-Lefko P.J., Barry-Shaw J., Greenberg N.M., Gaudreau P., et al. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 2005, 24(29):4736-4740.
90. Sutherland B.W., Knoblaugh S.E., Kaplan-Lefko P.J., Wang F., Holzenberger M., Greenberg N.M. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res 2008, 68(9):3495-3504.
91. Chiaverotti T., Couto S.S., Donjacour A., Mao J.H., Nagase H., Cardiff R.D., et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008, 172(1):236-246.
92. Nelson E.C., Cambio A.J., Yang J.C., Ok J.H., Lara P.N., Evans C.P. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 2007, 10(1):6-14.
93. Kasper S., Sheppard P.C., Yan Y., Pettigrew N., Borowsky A.D., Prins G.S., et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998, 78(6):i-xv.
94. Masumori N., Thomas T.Z., Chaurand P., Case T., Paul M., Kasper S., et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001, 61(5):2239-2249.
95. Klezovitch O., Chevillet J., Mirosevich J., Roberts R.L., Matusik R.J., Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004, 6(2):185-195.
96. Gabril M.Y., Onita T., Ji P.G., Sakai H., Chan F.L., Koropatnick J., et al. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther 2002, 9(23):1589-1599.
97. Garabedian E.M., Humphrey P.A., Gordon J.I. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci USA 1998, 95(26):15382-15387.
98. Perez-Stable C., Altman N.H., Brown J., Harbison M., Cray C., Roos B.A. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Lab Invest 1996, 74(2):363-373.
99. Hill R., Song Y., Cardiff R.D., Van Dyke T. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res 2005, 65(22):10243-10254.
100. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18(1):11-22.
101. Zhou Z., Flesken-Nikitin A., Corney D.C., Wang W., Goodrich D.W., Roy-Burman P., et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 2006, 66(16):7889-7898.
102. Tzeng Y.J., Guhl E., Graessmann M., Graessmann A. Breast cancer formation in transgenic animals induced by the whey acidic protein SV40T antigen (WAP-SV-T) hybrid gene. Oncogene 1993, 8(7):1965-1971.
103. Tzeng Y.J., Zimmermann C., Guhl E., Berg B., Avantaggiati M.L., Graessmann A. SV40T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors. Oncogene 1998, 16(16):2103-2114.
104. Santarelli R., Tzeng Y.J., Zimmermann C., Guhl E., Graessmann A. SV40 T-antigen induces breast cancer formation with a high efficiency in lactating and virgin WAP-SV-T transgenic animals but with a low efficiency in ovariectomized animals. Oncogene 1996, 12(3):495-505.
105. Schulze-Garg C., Lohler J., Gocht A., Deppert W. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 2000, 19(8):1028-1037.
106. Schulze-Garg C., Lohler J., Gocht A., Deppert W. WAP-TAg transgenic mice and the study of dysregulated cell survival: proliferation, and mutation during breast carcinogenesis. Oncogene 2000, 19(8):1010-1019.
107. Furth P.A. SV40 rodent tumour models as paradigms of human disease: transgenic mouse models. Dev Biol Stand 1998, 94:281-287.
108. Otto B., Gruner K., Heinlein C., Wegwitz F., Nollau P., Ylstra B., et al. Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression. Int J Cancer 2013, 132(6):1300-1310.
109. Shi H.Y., Zhang W., Liang R., Kittrell F., Templeton N.S., Medina D., et al. Modeling human breast cancer metastasis in mice: maspin as a paradigm. Histol Histopathol 2003, 18(1):201-206.
110. Rampetsreiter P., Casanova E., Eferl R. Genetically modified mouse models of cancer invasion and metastasis. Drug Discov Today: Dis Models 2011, 8(2-3):67-74.
111. Otto B., Streichert T., Wegwitz F., Gevensleben H., Klatschke K., Wagener C., et al. Transcription factors link mouse WAP-T mammary tumors with human breast cancer. Int J Cancer 2013, 132(6):1311-1322.
112. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
113. Hennighausen L. Mouse models for breast cancer. Oncogene 2000, 19(8):966-967.
114. Herschkowitz J.I., He X., Fan C., Perou C.M. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008, 10(5):R75.
115. Green J.E., Shibata M.A., Yoshidome K., Liu M.L., Jorcyk C., Anver M.R., et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000, 19(8):1020-1027.
116. Yoshidome K., Shibata M.A., Couldrey C., Korach K.S., Green J.E. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptor alpha expression during tumor progression. Cancer Res 2000, 60(24):6901-6910.
117. Ganesan A.P., Johansson M., Ruffell B., Beltran A., Lau J., Jablons D.M., et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol 2013, 191(4):2009-2017.
118. Meuwissen R., Berns A. Mouse models for human lung cancer. Genes Dev 2005, 19(6):643-664.
119. DeMayo F.J., Finegold M.J., Hansen T.N., Stanley L.A., Smith B., Bullock D.W. Expression of SV40T antigen under control of rabbit uteroglobin promoter in transgenic mice. Am J Physiol 1991, 261(2 Pt 1):L70-L76.
120. Sandmoller A., Halter R., Gomez-La-Hoz E., Grone H.J., Suske G., Paul D., et al. The uteroglobin promoter targets expression of the SV40T antigen to a variety of secretory epithelial cells in transgenic mice. Oncogene 1994, 9(10):2805-2815.
121. Magdaleno S.M., Wang G., Mireles V.L., Ray M.K., Finegold M.J., DeMayo F.J. Cyclin-dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice. Cell Growth Differ 1997, 8(2):145-155.
122. Hicks S.M., Vassallo J.D., Dieter M.Z., Lewis C.L., Whiteley L.O., Fix A.S., et al. Immunohistochemical analysis of Clara cell secretory protein expression in a transgenic model of mouse lung carcinogenesis. Toxicology 2003, 187(2-3):217-228.
123. de Seranno S., Meuwissen R. Progress and applications of mouse models for human lung cancer. Eur Respir J 2010, 35(2):426-443.
124. van Zandwijk N., Mooi W.J., Rodenhuis S. Prognostic factors in NSCLC. Recent experiences. Lung Cancer 1995, 12(Suppl 1):S27-S33.
125. Sekido Y., Fong K.M., Minna J.D. Molecular genetics of lung cancer. Annu Rev Med 2003, 54:73-87.
126. Wikenheiser K.A., Clark J.C., Linnoila R.I., Stahlman M.T., Whitsett J.A. Simian virus 40 large T antigen directed by transcriptional elements of the human surfactant protein C gene produces pulmonary adenocarcinomas in transgenic mice. Cancer Res 1992, 52(19):5342-5352.
127. Meuwissen R., Linn S.C., Linnoila R.I., Zevenhoven J., Mooi W.J., Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003, 4(3):181-189.
128. Linnoila R.I., Zhao B., DeMayo J.L., Nelkin B.D., Baylin S.B., DeMayo F.J., et al. Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice. Cancer Res 2000, 60(15):4005-4009.
129. Wikenheiser-Brokamp K.A. Rb family proteins differentially regulate distinct cell lineages during epithelial development. Development 2004, 131(17):4299-4310.
130. Robinson C., van Bruggen I., Segal A., Dunham M., Sherwood A., Koentgen F., et al. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res 2006, 66(22):10786-10794.
131. Robinson C., Walsh A., Larma I., O'Halloran S., Nowak A.K., Lake R.A. MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma. Eur J Cancer 2011, 47(1):151-161.
132. Robinson C., Woo S., Walsh A., Nowak A.K., Lake R.A. The antioxidants vitamins A and E and selenium do not reduce the incidence of asbestos-induced disease in a mouse model of mesothelioma. Nutr Cancer 2012, 64(2):315-322.
133. Cristaudo A., Foddis R., Vivaldi A., Buselli R., Gattini V., Guglielmi G., et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 2005, 65(8):3049-3052.
134. McDonald J.C., McDonald A.D. The epidemiology of mesothelioma in historical context. Eur Respir J 1996, 9(9):1932-1942.
135. Carbone M., Kratzke R.A., Testa J.R. The pathogenesis of mesothelioma. Semin Oncol 2002, 29(1):2-17.
136. Nutt J.E., Razak A.R., O'Toole K., Black F., Quinn A.E., Calvert A.H., et al. The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer 2010, 102(3):553-560.
137. Procopio A., Strizzi L., Vianale G., Betta P., Puntoni R., Fontana V., et al. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer 2000, 29(2):173-179.
138. Husain A.N., Colby T., Ordonez N., Krausz T., Attanoos R., Beasley M.B., et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2012, 137:647-667.
139. Dutertre M., Gouedard L., Xavier F., Long W.Q., di Clemente N., Picard J.Y., et al. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Endocrinology 2001, 142(9):4040-4046.
140. Connolly D.C., Bao R., Nikitin A.Y., Stephens K.C., Poole T.W., Hua X., et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003, 63(6):1389-1397.
141. Hensley H., Quinn B.A., Wolf R.L., Litwin S.L., Mabuchi S., Williams S.J., et al. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol Ther 2007, 6(11):1717-1725.
142. Mabuchi S., Altomare D.A., Connolly D.C., Klein-Szanto A., Litwin S., Hoelzle M.K., et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007, 67(6):2408-2413.
143. Hensley H.H., Roder N.A., O'Brien S.W., Bickel L.E., Xiao F., Litwin S., et al. Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice. Neoplasia 2012, 14(6):451-462.
144. Nunez-Cruz S., Gimotty P.A., Guerra M.W., Connolly D.C., Wu Y.Q., DeAngelis R.A., et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 2012, 14(11):994-1004.
145. Laviolette L.A., Garson K., Macdonald E.A., Senterman M.K., Courville K., Crane C.A., et al. 17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology 2010, 151(3):929-938.
146. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474(7353):609-615.
147. Flesken-Nikitin A., Choi K.C., Eng J.P., Shmidt E.N., Nikitin A.Y. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003, 63(13):3459-3463.
148. Clark-Knowles K.V., Senterman M.K., Collins O., Vanderhyden B.C. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS ONE 2009, 4(12):e8534.
149. Szabova L., Yin C., Bupp S., Guerin T.M., Schlomer J.J., Householder D.B., et al. Perturbation of Rb: p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 2012, 72(16):4141-4153.
150. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28(6):622-629.
151. Murphy D., Bishop A., Rindi G., Murphy M.N., Stamp G.W., Hanson J., et al. Mice transgenic for a vasopressin-SV40 hybrid oncogene develop tumors of the endocrine pancreas and the anterior pituitary. A possible model for human multiple endocrine neoplasia type 1. Am J Pathol 1987, 129(3):552-566.
152. Ornitz D.M., Hammer R.E., Messing A., Palmiter R.D., Brinster R.L. Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science 1987, 238(4824):188-193.
153. Ornitz D.M., Palmiter R.D., Messing A., Hammer R.E., Pinkert C.A., Brinster R.L. Elastase I promoter directs expression of human growth hormone and SV40T antigen genes to pancreatic acinar cells in transgenic mice. Cold Spring Harb Symp Quant Biol 1985, 50:399-409.
154. Ceci J.D., Kovatch R.M., Swing D.A., Jones J.M., Snow C.M., Rosenberg M.P., et al. Transgenic mice carrying a murine amylase 2.2/SV40T antigen fusion gene develop pancreatic acinar cell and stomach carcinomas. Oncogene 1991, 6(2):323-332.
155. Tilli M.T., Frech M.S., Steed M.E., Hruska K.S., Johnson M.D., Flaws J.A., et al. Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol 2003, 163(5):1713-1719.
156. Chailley-Heu B., Rambaud C., Barlier-Mur A.M., Galateau-Salle F., Perret C., Capron F., et al. A model of pulmonary adenocarcinoma in transgenic mice expressing the simian virus 40T antigen driven by the rat Calbindin-D9K (CaBP9K) promoter. J Pathol 2001, 195(4):482-489.
157. Zhang Z.T., Pak J., Shapiro E., Sun T.T., Wu X.R. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999, 59(14):3512-3517.
158. Grippo P.J., Sandgren E.P. Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am J Pathol 2000, 157(3):805-813.
159. Dubois N., Bennoun M., Allemand I., Molina T., Grimber G., Daudet-Monsac M., et al. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J Hepatol 1991, 13(2):227-239.
160. Lou D.Q., Molina T., Bennoun M., Porteu A., Briand P., Joulin V., et al. Conditional hepatocarcinogenesis in mice expressing SV 40 early sequences. Cancer Lett 2005, 229(1):107-114.
161. Butel J.S., Sepulveda A.R., Finegold M.J., Woo S.L. SV40 large T antigen directed by regulatory elements of the human alpha-1-antitrypsin gene. A transgenic mouse system that exhibits stages in liver carcinogenesis. Intervirology 1990, 31(2-4):85-100.
162. Araki K., Hino O., Miyazaki J., Yamamura K. Development of two types of hepatocellular carcinoma in transgenic mice carrying the SV40 large T-antigen gene. Carcinogenesis 1991, 12(11):2059-2062.
163. Sandgren E.P., Quaife C.J., Pinkert C.A., Palmiter R.D., Brinster R.L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 1989, 4(6):715-724.
164. Cullen J.M., Sandgren E.P., Brinster R.L., Maronpot R.R. Histologic characterization of hepatic carcinogenesis in transgenic mice expressing SV40 T-antigens. Vet Pathol 1993, 30(2):111-118.
165. Kitagawa T., Hino O., Lee G.H., Li H., Liu J., Nomura K., et al. Multistep hepatocarcinogenesis in transgenic mice harboring SV40 T-antigen gene. Princess Takamatsu Symp 1991, 22:349-360.
166. Manickan E., Satoi J., Wang T.C., Liang T.J. Conditional liver-specific expression of simian virus 40T antigen leads to regulatable development of hepatic neoplasm in transgenic mice. J Biol Chem 2001, 276(17):13989-13994.
167. Schirmacher P., Held W.A., Yang D., Biempica L., Rogler C.E. Selective amplification of periportal transitional cells precedes formation of hepatocellular carcinoma in SV40 large tag transgenic mice. Am J Pathol 1991, 139(1):231-241.
168. Held W.A., Mullins J.J., Kuhn N.J., Gallagher J.F., Gu G.D., Gross K.W. T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein/SV40T antigen hybrid gene. EMBO J 1989, 8(1):183-191.
169. Bradl M., Klein-Szanto A., Porter S., Mintz B. Malignant melanoma in transgenic mice. Proc Natl Acad Sci USA 1991, 88(1):164-168.
170. Anand R., Ma D., Alizadeh H., Comerford S.A., Sambrook J.F., Gething M.J., et al. Characterization of intraocular tumors arising in transgenic mice. Invest Ophthalmol Vis Sci 1994, 35(9):3533-3539.
171. Syed N.A., Windle J.J., Darjatmoko S.R., Lokken J.M., Steeves R.A., Chappell R., et al. Transgenic mice with pigmented intraocular tumors: tissue of origin and treatment. Invest Ophthalmol Vis Sci 1998, 39(13):2800-2805.
172. Penna D., Schmidt A., Beermann F. Tumors of the retinal pigment epithelium metastasize to inguinal lymph nodes and spleen in tyrosinase-related protein 1/SV40T antigen transgenic mice. Oncogene 1998, 17(20):2601-2607.
173. O'Brien J.M., Marcus D.M., Niffenegger A.S., Bernards R., Carpenter J.L., Windle J.J., et al. Trilateral retinoblastoma in transgenic mice. Trans Am Ophthalmol Soc 1989, 87:301-322. [discussion 322-6].
174. Windle J.J., Albert D.M., O'Brien J.M., Marcus D.M., Disteche C.M., Bernards R., et al. Retinoblastoma in transgenic mice. Nature 1990, 343(6259):665-669.
175. Wadhwa L., Bond W.S., Perlaky L., Overbeek P.A., Hurwitz M.Y., Chevez-Barrios P., et al. Embryonic retinal tumors in SV40 T-Ag transgenic mice contain CD133+ tumor-initiating cells. Invest Ophthalmol Vis Sci 2012, 53(7):3454-3462.